Cooperative Assessment of Late Effects for SCD Curative Therapies | MicrobiomeTrials← Back to trialsNCT05153967
Cooperative Assessment of Late Effects for SCD Curative Therapies
RecruitingOBSERVATIONAL
Trial Details
Start: 2022-07-12Est. Completion: 2026-11
Enrollment target: 750 participants Locations- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Emory University School of Medicine, Atlanta, Georgia, United States
- Johns Hopkins Hospital, Baltimore, Maryland, United States
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
- Vanderbilt University Medical Center, Nashville, Tennessee, United States
Other microbiome trials you might be interested in
Sickle Cell Disease, Hemolytic Anemia
Background:
Sickle cell disease (SCD) is an inherited blood disorder. The disease affects the ability of red blood cell…
Bethesda, United StatesEst. completion Apr 27, 2027
Sickle Cell Disease
This is a follow-up trial to NYMC 526 (NCT01461837) to assess the safety, efficacy and toxicity of administering Defibro…
Los Angeles, United StatesEst. completion Dec 2026
Kristin Wuichet, PhD